GGrantIndex
← Leaderboards

Paul Nghiem

Harvard University

$19,814,556
Attributed
$19,814,556
Total exposure
15
Grants
14
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $4.5M · FY200525
$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$36,781,613 · 16

By mechanism

P01$22,986,507 · 7
R01$9,840,712 · 4
K24$1,809,070 · 1
RC2$1,000,000 · 1
K02$508,626 · 1
K08$487,928 · 1

Top collaborators

No co-investigators on record.

Most similar at Harvard University

Same institution · by research overlap

Others in their field

Top investigators on “Response

Research focus

ResponseMerkel Cell CarcinomaImmunotherapyMalignant NeoplasmsSkin CancerBaseTumorSpecimenPolyomavirusImmuneT-LymphocyteInsightMerkel CellsClinical TrialsBiologyVirusIncidenceProgramsImmune ResponseBiologicalAntigensIn VivoPathway InteractionsCells

Grant awards (73)

Immunobiology and Immune Therapy for Merkel Cell Carcinoma$2,994,993
P01 · FY2025 · CA · contact PI
Understand & overcome resistance to PD-1$432,274
P01 · FY2025 · CA · contact PI
Specimen and Data Core$344,967
P01 · FY2025 · CA · contact PI
Admin Core$216,978
P01 · FY2025 · CA · contact PI
Immunobiology and Immune Therapyfor Merkel Cell Carcinoma$2,556,762
P01 · FY2023 · CA · contact PI
Project 2: Characterizing and overcoming failure to respond to PD-1 blockade therapy$367,998
P01 · FY2023 · CA · contact PI
Core 1: Specimen and Data Core$333,438
P01 · FY2023 · CA · contact PI
Administrative Core$247,876
P01 · FY2023 · CA · contact PI
Immunobiology and Immune Therapyfor Merkel Cell Carcinoma$2,912,785
P01 · FY2022 · CA · contact PI
Project 2: Characterizing and overcoming failure to respond to PD-1 blockade therapy$407,751
P01 · FY2022 · CA · contact PI
Core 1: Specimen and Data Core$350,560
P01 · FY2022 · CA · contact PI
Administrative Core$187,652
P01 · FY2022 · CA · contact PI
Immunobiology and Immune Therapy for Merkel Cell Carcinoma$2,988,939
P01 · FY2021 · CA · contact PI
Project 2: Characterizing and overcoming failure to respond to PD-1 blockade therapy$428,711
P01 · FY2021 · CA · contact PI
Core 1: Specimen and Data Core$387,261
P01 · FY2021 · CA · contact PI
Administrative Core$284,645
P01 · FY2021 · CA · contact PI
Immunobiology and Immune Therapy for Merkel Cell Carcinoma$2,996,200
P01 · FY2020 · CA · contact PI
Project 2: Characterizing and overcoming failure to respond to PD-1 blockade therapy$421,755
P01 · FY2020 · CA · contact PI
Mechanisms of UV-Induced DNA Damage Responses and Carcinogenesis in Skin$382,800
R01 · FY2020 · AR · contact PI
Core 1: Specimen and Data Core$381,205
P01 · FY2020 · CA · contact PI
Administrative Core$280,813
P01 · FY2020 · CA · contact PI
Immunobiology and Immune Therapy for Merkel Cell Carcinoma$2,517,378
P01 · FY2019 · CA · contact PI
Mechanisms of UV-Induced DNA Damage Responses and Carcinogenesis in Skin$382,800
R01 · FY2019 · AR · contact PI
Project 2: Characterizing and overcoming failure to respond to PD-1 blockade therapy$364,007
P01 · FY2019 · CA · contact PI
Core 1: Specimen and Data Core$331,286
P01 · FY2019 · CA · contact PI
Administrative Core$250,273
P01 · FY2019 · CA · contact PI
Mechanisms of UV-induced DNA damage responses and carcinogenesis in skin$125,140
R01 · FY2019 · AR · contact PI
Mechanisms of UV-Induced DNA Damage Responses and Carcinogenesis in Skin$382,800
R01 · FY2018 · AR · contact PI
Pathogenetic and prognostic studies for improved therapy of Merkel cell carcinoma$176,007
K24 · FY2018 · CA · contact PI
Pathogenetic and prognostic studies for improved therapy of Merkel cell carcinoma$176,007
K24 · FY2017 · CA · contact PI
Viral oncoprotein targeted immune therapy for Merkel cell carcinoma$637,515
R01 · FY2016 · CA · contact PI
Mechanisms of UV-induced DNA damage responses and carcinogenesis in skin$382,800
R01 · FY2016 · AR · contact PI
Pathogenetic and prognostic studies for improved therapy of Merkel cell carcinoma$176,007
K24 · FY2016 · CA · contact PI
Viral oncoprotein targeted immune therapy for Merkel cell carcinoma$637,515
R01 · FY2015 · CA · contact PI
Mechanisms of UV-induced DNA damage responses and carcinogenesis in skin$382,800
R01 · FY2015 · AR · contact PI
Humoral and cellular immunity in polyomavirus-linked Merkel cell carcinoma$329,674
R01 · FY2015 · CA · contact PI
Pathogenetic and prognostic studies for improved therapy of Merkel cell carcinoma$176,007
K24 · FY2015 · CA · contact PI
Viral oncoprotein targeted immune therapy for Merkel cell carcinoma$621,892
R01 · FY2014 · CA · contact PI
The replication checkpoint and genomic fidelity in skin$341,668
R01 · FY2014 · AR · contact PI
Humoral and cellular immunity in polyomavirus-linked Merkel cell carcinoma$319,784
R01 · FY2014 · CA · contact PI
Pathogenetic and prognostic studies for improved therapy of Merkel cell carcinoma$176,007
K24 · FY2014 · CA · contact PI
Viral oncoprotein targeted immune therapy for Merkel cell carcinoma$660,665
R01 · FY2013 · CA · contact PI
The replication checkpoint and genomic fidelity in skin$334,455
R01 · FY2013 · AR · contact PI
Humoral and cellular immunity in polyomavirus-linked Merkel cell carcinoma$309,895
R01 · FY2013 · CA · contact PI
Pathogenetic and prognostic studies for improved therapy of Merkel cell carcinoma$185,016
K24 · FY2013 · CA · contact PI
Training for Investigative Dermatology$148,770
T32 · FY2013 · AR · contact PI
The replication checkpoint and genomic fidelity in skin$355,511
R01 · FY2012 · AR · contact PI
Humoral and cellular immunity in polyomavirus-linked Merkel cell carcinoma$329,671
R01 · FY2012 · CA · contact PI
Pathogenetic and prognostic studies for improved therapy of Merkel cell carcinoma$185,016
K24 · FY2012 · CA · contact PI
The replication checkpoint and genomic fidelity in skin$412,130
R01 · FY2011 · AR · contact PI
Humoral and cellular immunity in polyomavirus-linked Merkel cell carcinoma$346,175
R01 · FY2011 · CA · contact PI
Pathogenetic and prognostic studies for improved therapy of Merkel cell carcinoma$185,016
K24 · FY2011 · CA · contact PI
Targeting MCPyV to Overcome Immune Evasion in Merkel Cell Carcinoma$500,000
RC2 · FY2010 · CA · contact PI
The replication checkpoint and genomic fidelity in skin$442,018
R01 · FY2010 · AR · contact PI
Pathogenetic and prognostic studies for improved therapy of Merkel cell carcinoma$188,971
K24 · FY2010 · CA · contact PI
Targeting MCPyV to Overcome Immune Evasion in Merkel Cell Carcinoma$500,000
RC2 · FY2009 · CA · contact PI
Pathogenetic and prognostic studies for improved therapy of Merkel cell carcinoma$185,016
K24 · FY2009 · CA · contact PI
The replication checkpoint and genomic fidelity in skin$99,792
K02 · FY2008 · AR · contact PI
The replication checkpoint and genomic fidelity in skin$316,960
R01 · FY2007 · AR · contact PI
The replication checkpoint and genomic fidelity in skin$99,792
K02 · FY2007 · AR · contact PI
The replication checkpoint and genomic fidelity in skin$326,427
R01 · FY2006 · AR · contact PI
The replication checkpoint and genomic fidelity in skin$99,792
K02 · FY2006 · AR · contact PI
The replication checkpoint and genomic fidelity in skin$353,781
R01 · FY2005 · AR
The replication checkpoint and genomic fidelity in skin$61,965
K02 · FY2005 · AR
The replication checkpoint and genomic fidelity in skin$43,065
K02 · FY2005 · AR
The replication checkpoint and genomic fidelity in skin$362,918
R01 · FY2004 · AR
The replication checkpoint and genomic fidelity in skin$104,220
K02 · FY2004 · AR
Replication checkpoint and genomic fidelity in skin$362,918
R01 · FY2003 · AR
PIK RELATED KINASES IN THE RESPONSE TO DNA DAMAGE BY UV$122,282
K08 · FY2003 · AR
PIK RELATED KINASES IN THE RESPONSE TO DNA DAMAGE BY UV$76,067
K08 · FY2002 · AR
PIK RELATED KINASES IN THE RESPONSE TO DNA DAMAGE BY UV$45,815
K08 · FY2002 · AR
PIK RELATED KINASES IN THE RESPONSE TO DNA DAMAGE BY UV$121,882
K08 · FY2001 · AR
PIK RELATED KINASES IN THE RESPONSE TO DNA DAMAGE BY UV$121,882
K08 · FY2000 · AR